Hormonal
GLP-1 agonists (specifically Semaglutide and Liraglutide) induce significant weight loss (≥15%) which improves Obstructive Sleep Apnoea (OSA) severity, measured by Apnoea-Hypopnoea Index (AHI), particularly in patients who cannot tolerate CPAP.
If you have OSA and struggle with CPAP or cannot lose enough weight through diet alone, GLP-1 agonists like Semaglutide (2.4mg weekly) are a clinically proven option to reduce sleep apnea severity. Be prepared for potential gastrointestinal side effects and the likelihood that you may need to stay on the medication long-term to keep the weight off and your airway open.
with high dose Semaglutide (Wegovy™) at 2.4 mg once weekly via subcutaneous injection in non-diabetic obese patients, over 50% of patients achieved and sustained at least a 15% weight loss... the SCALE Sleep Apnoea randomized controlled trial (RCT) demonstrated that Liraglutide improved AHI in OSA subjects unwilling or unable to use continuous positive airway pressure (CPAP).
Why this rating
Supported by RCT data (SCALE Sleep Apnoea) and high-dose trials for Semaglutide, though the paper notes direct evidence for OSA is still 'limited' and more trials are ongoing.
Source
The potential impact of <scp>GLP</scp>‐1 agonists on obstructive sleep apnoea
Garun S. Hamilton et al. · Respirology · 2023
DOI 10.1111/resp.14545
More from this paper
- GLP-1 agonists reduce cardiovascular risk and all-cause mortality in diabetic populations, offering a secondary benefit for OSA patients who have high cardiometabolic risk.Strong
- GLP-1 agonists are likely unaffordable for universal healthcare systems due to high prevalence of OSA and high drug costs, potentially exacerbating healthcare inequities.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →